Radiopharm Theranostics Limited - American Depositary Shares (RADX) Stock Price, News & Analysis

Company Overview

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

Key Stats

• Today's Range: $3.99 to $4.25
• 50-Day Range: N/A
• 52-Week Range: $3.50 to $50.82
• Volume: 9,155 shs
• Average Volume: 167,436 shs
• Market Capitalization: $30.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

RADX Stock Analysis - Frequently Asked Questions

How have RADX shares performed this year?

Radiopharm Theranostics Limited - American Depositary Shares' stock was trading at $4.00 at the beginning of 2025. Since then, RADX stock has increased by 1.3% and is now trading at $4.05.
View the best growth stocks for 2025 here.

How do I buy shares of Radiopharm Theranostics Limited - American Depositary Shares?

Shares of RADX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RADX
• CIK: 1949257
• Web: N/A
• Phone: N/A
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.68 million
• Price / Sales: 17.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,506,000
• Free Float: N/A
• Market Cap: $29.35 million
• Optionable: N/A
• Beta: N/A